Amwise Diagnostics
Developing patented genetic analysis technology to assist doctors and patients in determining the most appropriate individualized cancer treatment.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
$10.0m | Series B | ||
| Total Funding | 000k | ||
Related Content
Amwise Diagnostics specializes in advanced genomic diagnostics focused on breast cancer. The company serves healthcare providers, oncologists, and medical institutions by offering precise genomic tests that predict breast cancer recurrence and guide treatment decisions. Operating in the healthcare and biotechnology market, Amwise Diagnostics employs a B2B (business-to-business) model, generating revenue through the sale of diagnostic tests and related services to medical professionals and institutions. The company's core product is an 18-gene based clinical genomic model that provides accurate predictions for early-stage breast cancer recurrence, aiding in personalized treatment plans. By leveraging cutting-edge genomic research and technology, Amwise Diagnostics aims to improve patient outcomes and optimize treatment strategies.
Keywords: genomic diagnostics, breast cancer, recurrence prediction, personalized treatment, healthcare, biotechnology, oncologists, medical institutions, precision medicine, clinical genomic model.